Product logins

Find logins to all Clarivate products below.


Atopic Dermatitis/Atopic Eczema | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2019

Atopic dermatitis (AD) disproportionately affects children and adolescents, and its intermittent flares of itchy rash profoundly affect their quality of life. Most pediatric patients use prescribed topical corticosteroids for their symptoms; systemic immunomodulators are reserved for severe refractory cases. Pfizer’s nonsteroidal topical agent Eucrisa and Sanofi/Regeneron’s Dupixent—for which we expect FDA approval for adolescent AD patients in 2019—bring new options to distinct points in the AD treatment algorithm. This claims data analysis assesses how these novel agents have begun to be integrated into patients’ treatment, as well as how they compare with the therapeutic mainstays.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric AD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric AD patients?
  • How have Dupixent and Eucrisa been integrated into the treatment algorithm for pediatric AD, and what are their sources of business?
  • What percentage of pediatric AD patients receive drug therapy within one year of diagnosis, and how quickly do they receive it? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of pediatric AD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations? What are the product-level compliance and persistency rates among drug-treated pediatric AD patients?

GEOGRAPHIES

United States

KEY DRUGS COVERED

Dupixent, Eucrisa, Protopic, Elidel, cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, topical corticosteroids

KEY ANALYSIS PROVIDED

Brand/therapy usage across a longitudinal patient sample.

Newly diagnosed patient analysis.

Treatment initiation and progression.

Line of therapy analysis.

Combination therapy analysis.

Source of business for recently treated patients.

Persistency and compliance analysis.

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Asthma – Access & Reimbursement – Access & Reimbursement – Asthma (US)
The dynamics within the LABA/ICS FDC, LAMA, LABA/LAMA/ICS FDC, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GSK’s…
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…